ArticleBioinformation2013
In silico synteny based comparative genomics approach for identification and characterization of novel therapeutic targets in Chlamydophila pneumoniae.
Article in Bioinformation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 5 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlamydophila pneumoniae is one of the most important and well studied gram negative bacterial strain with respect to community acquired pneumonia and other respiratory diseases like Chronic obstructive pulmonary disease (COPD), Chronic asthma, Alzheimer's disease, Atherosclerosis and Multisclerosis which have a great potential to infect humans and many other mammals. According to WHO prediction, COPD is to become the third leading cause of death by 2030. Unfortunately, the molecular mechanisms leading to chronic infections are poorly understood and the difficulty in culturing C pneumoniae in experimental conditions and lack of entirely satisfactory serological methods for diagnosis is also a hurdle for drug discovery and development. We have performed an insilico synteny based comparative genomics analysis of C pneumoniae and other eight Chlamydial organisms to know the potential of C pneumoniae which cause COPD but other Chlamydial organisms lack in potential to cause COPD though some are involved in human pathogenesis. We have identified total 354 protein sequences as non-orthologous to other Chlamydial organisms, except hypothetical proteins 70 were found functional out of which 60 are non homologous to Homo sapiens proteome and among them 18 protein sequences are found to be essential for survival of the C pneumoniae based on BLASTP search against DEG database of essential genes. CELLO analysis results showed that about 80% proteins are found to be cytoplasmic, Among which 5 were found as bacterial exotoxins and 2 as bacterial endotoxins, remaining 11 proteins were found to be involved in DNA binding, RNA binding, catalytic activity, ATP binding, oxidoreductase activity, hydrolase activity and proteolysis activity. It is expected that our data will facilitate selection of C pneumoniae proteins for successful entry into drug design pipelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.